After-Hours Decliners: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Brighthouse Financial, Inc. (NASDAQ:BHF), Markel Corporation (NYSE:MKL), Lear Corporation (NYSE:LEA)


New data from an open-label extension study of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s Onpattro shows long-term efficacy and sustained treatment benefit for polyneuropathy of hereditary ATTR (hATTR) amyloidosis. The long-term data shows the drugs ability to reverse or halt neuropathy progression, the company said. Over the weekend, Cambridge, Mass.-based Alnylam presented the data from the Global Open Label Extension study at the 2019 Peripheral Nerve Society (PNS) Annual Meeting in Italy, as well as a new analysis from the APOLLO Phase III study of patisiran. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a Healthcare sector firm, traded 479560 shares in last trading session with closing price of $71.80 per share. Company gross margin stands at 94.00% whereas its return on investment (ROI) is -59.70%. Stock value has moved between $60.34 – 123.79 in last one year. Analyst’s mean target price for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is $121.56 while analysts mean recommendation is 2.10. ALNY EPS growth this year is -39.80%.

On last trading day, Brighthouse Financial, Inc. (NASDAQ:BHF) shares closed at $38.12 per share. BHF market capitalization is 4453.94. Analyst’s mean target price for Brighthouse Financial, Inc. (NASDAQ:BHF) is $41.69 whereas analysts mean recommendation is 3.20. Its weekly performance is 1.25% while year to date (YTD) performance is 25.07%.

In last session Markel Corporation (NYSE:MKL) traded 23363 shares and was closed at $1077.75. Analyst’s mean target price for MKL is $1066.67 while analysts mean recommendation is 2.70. Company is -12.26% away from its 52 week high and is moving 13.43% ahead of its 52 week low. MKL return on assets is 1.50%. Markel Corporation (NYSE:MKL) quarterly performance is 9.34% while its price to sale ratio is 1.96.

Lear Corporation (NYSE:LEA), a Consumer Goods sector firm, traded 503569 shares on last trading day with closing price of $138.09 per share. Company gross margin stands at 11.00% whereas its return on investment (ROI) is 21.20%. Stock value has moved between $114.12 – 203.07 in last one year. Analyst’s mean target price for Lear Corporation (NYSE:LEA) is $171.50 while analysts mean recommendation is 2.10. LEA EPS growth this year is 2.70%.

Leave a Reply